{"id":816695,"date":"2025-02-24T10:30:37","date_gmt":"2025-02-24T15:30:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/singular-highlights-key-g4x-launch-milestones-and-showcases-groundbreaking-3d-spatial-multiomic-performance-at-agbt\/"},"modified":"2025-02-24T10:30:37","modified_gmt":"2025-02-24T15:30:37","slug":"singular-highlights-key-g4x-launch-milestones-and-showcases-groundbreaking-3d-spatial-multiomic-performance-at-agbt","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/singular-highlights-key-g4x-launch-milestones-and-showcases-groundbreaking-3d-spatial-multiomic-performance-at-agbt\/","title":{"rendered":"Singular Highlights Key G4X\u2122 Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBT"},"content":{"rendered":"
\n

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) — Singular Genomics Systems, Inc., an innovator in high-throughput spatial multiomics technologies designed to advance precision medicine, today announced key development milestones for its G4X\u2122 Spatial Sequencer at the Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida.<\/p>\n

\n G4X Early Access Program Ongoing and Broader Availability on Track<\/strong>\n <\/p>\n

The G4X Early Access Program is currently underway at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, providing valuable feedback highlighting the platform\u2019s real-world potential.<\/p>\n

\n \u201cAs the first early access site, we\u2019ve had the chance to appreciate the impact of the very high throughput of the G4X, along with its ability to generate high-quality data across multiple sample types, right from the start,\u201d\u00a0<\/em>said Dr.\u00a0Ioannis Vlachos, Director of the Spatial Technologies Unit (www.spatialtechnology.org<\/u><\/a>) at Beth Israel Deaconess Medical Center, and\u00a0Associate Professor of Pathology at Harvard Medical School.\u00a0\u201cThe system\u2019s higher throughput is squarely aligned with current needs of the spatial biology field, where increased sample volumes and lower turnaround times can enable larger studies, adoption into translational or clinical trial settings, as well as higher return-of-investment and reduced costs for researchers and core facilities.\u201d<\/em><\/p>\n

\n \u201cWe\u2019re excited to have the G4X in our lab, and the data we\u2019ve seen so far is promising for our work with the Human Tumor Atlas Network,\u201d<\/em> said Dr.\u00a0Tae\u00a0Hwang, Founding Director of the Molecular Artificial Intelligence Initiatives at Vanderbilt University Medical Center. \u201cThe reproducibility, speed,<\/em>\u00a0<\/em>and cost-efficiency allow us to scale 3D spatial analyses in larger retrospective clinical cohorts. Integrating the high-throughput spatial multimodal analysis of samples on G4X with AI can provide us critical insights into disease mechanisms and therapeutic biomarkers, ultimately advancing patient care.\u201d<\/em><\/p>\n

Singular plans to expand its early access program to a few more sites in Q2. Meanwhile, pre-orders for the G4X are now open, and initial shipments are on track for June 2025. Researchers wishing to start generating multiomic data can use Singular\u2019s technology access services in the meantime.<\/p>\n

\n \u201cThe G4X data we received back from Singular on our head and neck cancer sample cohort was highly informative,\u201d<\/em>\u00a0remarked Dr.\u00a0Shanye\u00a0Yin, Assistant Professor in the Department of Pathology at Albert Einstein College of Medicine and Director of the Pathology Single-Cell Core Laboratory. \u201cIntegrating transcript, protein, and fH&E data allowed us to identify cell populations and complex tumor-immune interactions with single-cell precision. Additionally, the system’s robustness is confirmed as the results are fully validated by other multi-plex imaging platforms.\u201d<\/em><\/p>\n

\n Exceptional Multiomic Performance and 3D Reconstruction Showcased<\/strong>\n <\/p>\n

At AGBT, Singular Genomics presented data demonstrating the G4X platform\u2019s robust integrated multiomic performance. Immune-oncology-focused lung, kidney, colon, and breast panels showed high sensitivity, specificity, and reproducibility in FFPE samples, providing comprehensive spatial insights into cancerous and healthy tissues.<\/p>\n

Building on these data, Singular showcased advanced 3D multi-omic reconstruction and niche detection from 10 serial renal cell carcinoma FFPE sections, over 6.2 million cells, and 438 million transcripts\u2014all from a single G4X flow cell.<\/p>\n

\n \u201cThe high throughput on the G4X ensures exceptional consistency across FFPE samples, while simultaneously measuring transcripts, proteins, and fH&E within the same sample provides strong reproducibility across modalities. This unique combination makes 3D reconstruction surprisingly straightforward,\u201d<\/em> said Michael Lawson, Director, R&D at Singular Genomics. \u201cAnalyzing tissues in a higher dimension facilitates advanced spatial neighborhood analyses of immune-tumor interactions, something we believe will translate into more robust biomarker identification.\u201d <\/em><\/p>\n

\n Additional Highlights<\/strong>\n <\/p>\n